Science News
from research organizations

Animal vaccine study yields insights that may advance HIV vaccine research

Date:
December 18, 2013
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.
Share:
         
Total shares:  
FULL STORY

A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research. Seven laboratories collaborated on the study led by Mario Roederer, Ph.D., and John R. Mascola, M.D., at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

By examining both viral amino-acid sequences and the animals' immune responses, the scientists could determine the mechanisms of protection from SIV infection. The study demonstrated that antibodies to the virus spikes that SIV uses to infect cells are necessary and sufficient to prevent SIV infection. The study also identified clear measures of immune responses in monkeys that predict protection from SIV infection.

Amid the genetically heterogeneous mix of SIV to which the vaccinated monkeys were exposed, vaccine-induced immune responses tended to block infection by those viruses sensitive to neutralization by SIV antibodies, while neutralization-resistant forms of SIV tended to cause infection. A two-amino-acid change to the spikes on SIV converted neutralization-sensitive SIV to neutralization-resistant SIV, and vice versa. A similar change to the spikes on HIV had a related effect. Thus, SIV and HIV escape the immune system in similar ways, the scientists discovered. They concluded that the reasons why future human HIV vaccine trials fail or succeed will become clearer if scientists integrate information on the amino-acid sequence and neutralization sensitivity or resistance of the infecting virus together with information about volunteers' immune responses to the vaccine.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mario Roederer, Brandon F. Keele, Stephen D. Schmidt, Rosemarie D. Mason, Hugh C. Welles, Will Fischer, Celia Labranche, Kathryn E. Foulds, Mark K. Louder, Zhi-Yong Yang, John-Paul M. Todd, Adam P. Buzby, Linh V. Mach, Ling Shen, Kelly E. Seaton, Brandy M. Ward, Robert T. Bailer, Raphael Gottardo, Wenjuan Gu, Guido Ferrari, S. Munir Alam, Thomas N. Denny, David C. Montefiori, Georgia D. Tomaras, Bette T. Korber, Martha C. Nason, Robert A. Seder, Richard A. Koup, Norman L. Letvin, Srinivas S. Rao, Gary J. Nabel, John R. Mascola. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2013; DOI: 10.1038/nature12893

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Animal vaccine study yields insights that may advance HIV vaccine research." ScienceDaily. ScienceDaily, 18 December 2013. <www.sciencedaily.com/releases/2013/12/131218133706.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2013, December 18). Animal vaccine study yields insights that may advance HIV vaccine research. ScienceDaily. Retrieved April 25, 2015 from www.sciencedaily.com/releases/2013/12/131218133706.htm
NIH/National Institute of Allergy and Infectious Diseases. "Animal vaccine study yields insights that may advance HIV vaccine research." ScienceDaily. www.sciencedaily.com/releases/2013/12/131218133706.htm (accessed April 25, 2015).

Share This Page:


Health & Medicine News
April 25, 2015

Latest Headlines
updated 12:56 pm ET